Pediatrix Medical Group, Inc. (NYSE:MD) Sees Significant Drop in Short Interest

Pediatrix Medical Group, Inc. (NYSE:MD) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 2,980,000 shares, a decline of 21.0% from the November 15th total of 3,770,000 shares. Based on an average daily volume of 674,100 shares, the days-to-cover ratio is presently 4.4 days. Currently, 3.5% of the company’s stock are short sold.

Wall Street Analyst Weigh In

MD has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft boosted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho lifted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Truist Financial increased their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Price Performance

MD stock traded down $0.10 during trading on Friday, hitting $14.07. 323,416 shares of the company’s stock traded hands, compared to its average volume of 851,323. The business has a fifty day simple moving average of $13.96 and a 200 day simple moving average of $10.73. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.60, a P/E/G ratio of 2.02 and a beta of 1.57. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.29 earnings per share. As a group, research analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its holdings in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares in the last quarter. SummerHaven Investment Management LLC increased its holdings in shares of Pediatrix Medical Group by 3.8% in the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock valued at $422,000 after purchasing an additional 2,069 shares during the period. Innealta Capital LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter worth about $33,000. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group during the second quarter worth about $31,000. Finally, Ballentine Partners LLC purchased a new stake in Pediatrix Medical Group in the second quarter valued at approximately $132,000. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.